HUTCHMED’s Orpathys and Tagrisso Combination Secures the NMPA’s Breakthrough Therapy Designation for Lung Cancer
Shots:
- The China’s NMPA has granted BTD to Orpathys (MET tyrosine kinase inhibitor) and Tagrisso (irreversible EGFR TKI) combination for treating locally advanced or metastatic EGFR+ NSCLC with MET amplification after progressing on EGFR inhibitor therapy
- The combination is being assessed under P-III (SACHI) study for its safety & efficacy in comparison with Pt-based doublet-CT (pemetrexed + cisplatin/carboplatin) to treat locally advanced or metastatic EGFR+ NSCLC
- The 1EP includes PFS by investigator evaluation while other EPs are PFS by IRC evaluation, OS, ORR, DoR, DCR, time to response (TTR) & safety
Ref: HUTCHMED | Image: HUTCHMED
Related News:- HUTCHMED and Innovent Report the NMPA’s Conditional Approval of Elunate Plus Tyvyt to Treat Advanced Endometrial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
